서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 121 to 161 of 161

Issue DateTitle / Author(s) / CitationFileAltmetrics
2019-09
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

Ock, Chan-Young; Yoo, Shin-Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong Wan; Chung, Doo Hyun; Heo, Dae Seog

The Korean Journal of Internal Medicine, Vol.34 No.5, pp.1116-1124

view fileDOI
2019-09
Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations

Lee, Yusoo; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog

Journal of Thoracic Oncology, Vol.14 No.9, pp.1556-1566

DOI
2019-10
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
DOI
2019-11
Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?
view fileDOI
2019-11
Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis
DOI
2019-11
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer
view fileDOI
2019-11
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer
view filelink
2020
Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
view fileDOI
2020
Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma
view fileDOI
2020-03
Clinical Application of Next-Generation Sequencing-Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies
view fileDOI
2020-07
Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors
DOI
2020-08
Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)
view filelink
2020-11
HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor

Chang, Hyeyeon; Shin, Yong-Won; Keam, Bhumsuk; Kim, Miso; Im, Seock-Ah; Lee, Soon-Tae

Annals of Clinical and Translational Neurology, Vol.7 No.11, pp.2243-2250

DOI
2020-12
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07
DOI
2020-12
Cell-Mediated Immunogenicity of Influenza Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors
DOI
2020-12
Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells
DOI
2021-01
Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients
DOI
2021-02
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
DOI
2021-03
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer
DOI
2021-06
Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy
DOI
2021-06
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues
DOI
2021-07
Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
DOI
2021-08
A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
2021-10
Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma Who Received Systemic Treatment
DOI
2021-10
Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment

Oh, So Yeon; Kim, Soyeon; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog

Scientific Reports, Vol.11 No.1, p. 19712

2021-10
Lymph Node Ratio after Neoadjuvant Chemotherapy for Stage II/III Breast Cancer: Prognostic Value Measured with Gini's Mean Difference of Restricted Mean Survival Times

Keam, Bhumsuk; Gorobets, Olena; Vinh-Hung, Vincent; Im, Seock-Ah

Cancer Informatics, Vol.20, pp.1-9

DOI
2021-11
Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR(T790M)-Mutant NSCLC
DOI
2022-01
Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01)
DOI
2022-01
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
DOI
2022-05
The impact of COVID-19 on cancer care in a tertiary hospital in Korea: possible collateral damage to emergency care

Yoo, Shin Hye; Sim, Jin-Ah; Shin, Jeongmi; Keam, Bhumsuk; Park, Jun -Bean; Shin, Aesun

Epidemiology and health, Vol.44, p. e2022044

DOI
2022-06
The impact of COVID-19 on screening for colorectal, gastric, breast, and cervical cancer in Korea

Park, Hyeree; Seo, Seung Hee; Park, Jong Heon; Yoo, Shin Hye; Keam, Bhumsuk; Shin, Aesun

Epidemiology and health, Vol.44, p. e2022053

DOI
2022-06
Comparable Clinical Outcome Using Small or Large Gross Tumor Volume-to-Clinical Target Volume Margin Expansion in Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
DOI
2022-07
Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis
DOI
2022-11
High tumor hexokinase-2 expression promotes a pro-tumorigenic immune microenvironment by modulating CD8+/regulatory T-cell infiltration
view fileDOI
2023-01
The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell lines
DOI
2023-04
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
DOI
2023-06
Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistance

Kim, Jung Sun; Kim, Soyeon; Koh, Jaemoon; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Lindmark, Bertil; Kim, Dong-Wan

Journal of Cancer Research and Clinical Oncology, Vol.149 No.6, pp.2355-2365

DOI
2023-10
Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Kim, Miso; Kim, Soyeon; Yim, Jeemin; Keam, Bhumsuk; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong-Wan; Heo, Dae Seog

Cancer Research and Treatment, Vol.55 No.4, pp.1134-1143

DOI
2023-10
Prognostic utility of body composition parameters based on computed tomography analysis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors
DOI
2023-10
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: A single-center, retrospective, longitudinal cohort study
DOI
2023-10
Prognostic utility of body composition parameters based on computed tomography analysis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors
view fileDOI
1 2 3